## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.8% below STRENGTH zone (4.0-10.0%); PEG 1.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.26)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams**
- Source: Business Wire | 20251216T130850 | Bullish | Relevance: 100%
- Hologic, Inc. announced new data showing its AI-powered mammography solution, Genius AI Detection, helped identify breast cancers initially missed in a study of 7,500 screening exams. The AI system flagged approximately one-third of false-negative cases and nearly 90% of previously identified cancers, accurately localizing suspicious areas. This study highlights AI's potential to improve breast cancer detection, especially for invasive ductal carcinomas.

**2. Hologic’s AI mammography tech flags previously missed breast cancers By Investing.com**
- Source: Investing.com Nigeria | 20251216T190837 | Bullish | Relevance: 100%
- Hologic, Inc. (NASDAQ:HOLX) announced new data showing its Genius AI Detection solution identified approximately one-third of previously missed breast cancers in a retrospective analysis. The AI system also flagged nearly 90% of previously identified breast cancer cases by radiologists, demonstrating significant potential for improving early detection. This innovation supports Hologic's strong financial performance, with the company reporting annual revenue of $4.1 billion.

**3. Hologic’s AI mammography tech flags previously missed breast cancers By Investing.com**
- Source: Investing.com Australia | 20251216T135541 | Bullish | Relevance: 100%
- Hologic, Inc. announced that its Genius AI Detection solution identified approximately one-third of previously missed breast cancers in a retrospective analysis. The AI system also accurately localized nearly 90% of previously identified breast cancer cases. This innovation contributes to Hologic's strong financial performance, with the company reporting annual revenue of $4.1 billion.

**4. Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams**
- Source: The Joplin Globe | 20251216T130850 | Bullish | Relevance: 100%
- A new study published in the American Journal of Roentgenology reveals that Hologic's Genius AI Detection solution identified approximately one-third of breast cancer cases initially missed by radiologists in a retrospective analysis of 7,500 digital breast tomosynthesis screening exams. The AI technology accurately localized cancers that were later diagnosed, highlighting its potential to improve breast cancer detection. Hologic emphasizes its commitment to innovation in women's health with AI-powered solutions.

**5. Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams**
- Source: Nasdaq | 20251216T130804 | Bullish | Relevance: 100%
- A new study published in the American Journal of Roentgenology found that Hologic's Genius AI® Detection solution for mammography screening flagged approximately one-third of breast cancer cases initially interpreted as negative. The AI technology also correctly localized nearly 90% of previously identified breast cancer cases. This highlights the potential of AI to improve breast cancer detection, though further research is needed.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($0.27M) |
| Sells | 25 ($6.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.66 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.5x). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.7B |
| Beta | 0.70 |
| 52W Range | $51.90 - $75.34 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.66 |
| Forward P/E | 15.0 |
| Current P/E | 16.4 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.8% over 5 days). Below STRENGTH zone by 3.2pp (needs >4.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.83% (CS: 48) | Neutral |
| RSI_14 | 62.3 | Neutral |
| MACD Histogram | -0.12 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.020x | Above |
| vs SMA200 | 1.139x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.94
- **Stop Loss:** $74.26 (0.9% risk)
- **Target:** $75.62 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1397
- **Position Value:** $104,691.18
- **Portfolio %:** 104.69%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*